AstraZeneca Tries To Use 'Orphan Drug' Designation To Extend Patent Life Of Top-Selling Pill
from the evergreen-desire-to-hang-to-intellectual-monopolies dept
At the heart of copyright and patents there is -- theoretically -- an implicit social contract. People are granted a time-limited, government-backed monopoly in return for allowing copyright material or patented techniques to enter the public domain once that period has expired. And yet copyright and patent holders often seem unwilling to respect the terms of that contract, as they seek to hang on to their monopolies beyond the agreed time in various ways.
In the case of copyright, this has been through repeated extensions of copyright's term, even though there is no economic justification for doing so. In the realm of pharma patents, a number of techniques have been employed. One is "pay for delay." Another is the granting of "data exclusivity." And a third is the use of "evergreening." Techdirt wrote about the last of these a while back, so it's no surprise that companies have continued to "innovate" in this field since then. For example, AstraZeneca is trying to use a variant of evergreening for its anti-cholesterol pill Crestor. As a New York Times article explains:
Crestor is the company’s best-selling drug, accounting for $5 billion of its $23.6 billion in product sales last year. About $2.8 billion in sales were in the United States, where the retail price is about $260 a month, according to GoodRx.com.
Here's how AstraZeneca hopes to hold on to that lucrative market, even though its patent on the drug is now coming to an end, and it should be entering the public domain:
The company is making a bold attempt to fend off impending generic competition to its best-selling drug, the anti-cholesterol pill Crestor, by getting it approved to treat [a] rare disease. In an unusual legal argument, the company says Crestor is entitled to seven years of additional market exclusivity under the Orphan Drug Act, a three-decade-old law that encourages pharmaceutical companies to develop treatments for rare diseases.
In May, AstraZeneca won approval of Crestor to treat children with the rare genetic disease of homozygous familial hypercholesterolemia (HoFH ). That gives it an additional seven-year patent on the drug, but only for that particular -- very small -- market. However, the designation means that detailed prescription information about using Crestor to treat children in this way must not be included on the label. AstraZeneca's clever lawyers are trying to turn that into an extended patent for all uses of the drug:
AstraZeneca immediately petitioned the F.D.A., arguing that if the correct dose for children with HoFH could not be on the generic label, then it would be illegal and dangerous to approve any generic versions for any use at all. That is because doctors might still prescribe the generic for children with HoFH and choose the wrong dose, posing "substantial safety and efficacy risks."
Needless to say, AstraZeneca was only asking for generic versions to be kept off the market for another seven years for safety reasons, not because doing so would bring it billions more in exclusive sales to the general population. Of course.
The New York Times article goes into more detail about the fascinating legal background to AstraZeneca's argument here, and notes that other drug companies have tried the same approach in the past, without success. Even if this particular ploy does fail again, we can be sure that pharma companies will be back with other sneaky ways of extending their patent monopolies -- implicit social contract be damned.
Follow me @glynmoody on Twitter or identi.ca, and +glynmoody on Google+
Thank you for reading this Techdirt post. With so many things competing for everyone’s attention these days, we really appreciate you giving us your time. We work hard every day to put quality content out there for our community.
Techdirt is one of the few remaining truly independent media outlets. We do not have a giant corporation behind us, and we rely heavily on our community to support us, in an age when advertisers are increasingly uninterested in sponsoring small, independent sites — especially a site like ours that is unwilling to pull punches in its reporting and analysis.
While other websites have resorted to paywalls, registration requirements, and increasingly annoying/intrusive advertising, we have always kept Techdirt open and available to anyone. But in order to continue doing so, we need your support. We offer a variety of ways for our readers to support us, from direct donations to special subscriptions and cool merchandise — and every little bit helps. Thank you.
–The Techdirt Team
Filed Under: blocking, competition, crestor, evergreening, fda, generics, new uses, patents
Companies: astrazeneca
Reader Comments
The First Word
“Subscribe: RSS
View by: Time | Thread
How can it be orphaned if others want to make it?
[ link to this | view in thread ]
Re: How can it be orphaned if others want to make it?
The total income would never recoup the advertising budget & development, so they don't bother looking.
So now a company went searching for one of those diseases to get their best seller approved to treat (something they never looked at until their billions might stop flowing) and then make moves to lock up 7 more years of being the only game in town. The R&D and the advertising budget was recouped long ago, and they have made huge profits... that they couldn't be bothered to use to find a treatment for a disease, they just want to cling to this one for as long as possible.
[ link to this | view in thread ]
[ link to this | view in thread ]
[ link to this | view in thread ]
The problem is now glaringly obvious
It's clear the patents make the companies lazy and averse to innovation. No sane company would make their business so dependent on one product that it accounts for more than 20% of their sales if they didn't think they could keep that position.
It's not like high cholesterol is the last disease in the world and there is nothing else to research. There exist plenty opportunities to diversify the portfolio a bit.
[ link to this | view in thread ]
Am I the only one that noticed they are doing it for the children? /sarcasm
No, really, let's screw some kids to get a few beeellions, shall we?
[ link to this | view in thread ]
Re:
[ link to this | view in thread ]
[ link to this | view in thread ]
The whole industry is corrupt and needs reformed
Then there is Xyrem, a drug first synthesized over a hundred years ago yet is patented, made by a single company and can only be dispensed by a single pharmacy thanks to the war on drugs. About ten years ago Xyrem was about $3,000 a month, its now over $10,000 a month. Must be nice to have a 99.99% profit margin.
[ link to this | view in thread ]
It's not good that companies are trying to do this, but it's important to note that they keep failing.
[ link to this | view in thread ]
[ link to this | view in thread ]
[ link to this | view in thread ]
One statin among many... are the ALL orphans?
[ link to this | view in thread ]
Re:
Keep an eye out for commercials that say "Do you fall asleep at 11:00pm? You might have night-time-sleepiness syndrome, a brand-new disease. Take Crestor and you won't fall asleep again."
[ link to this | view in thread ]
The drug that I took during the trial, Xeljanz, was already approved for treating arthritis, so my doctor wrote me a prescription for it. Medicaid took an additional two weeks to approve it. Why? Maybe the fact that it's $4,040.68 a month might have something to do with it!
Since I was off it for a month and a half, my arthritis got to the point where it may now take months to get back to where I was. If I get back there at all. During the study I was taking 20mg a day, but apparently it's only approved for 10mg a day, which is what I'm taking now.
On the plus side, it has almost completely cleared up my psoriasis, so there's that...
[ link to this | view in thread ]
Rosuvastatin is generic in Australia
Mayhaps your courts can follow in the same vein.
[ link to this | view in thread ]
Re: The whole industry is corrupt and needs reformed
For instance it is possible to die of a terribly ironic allergic reaction to an antihistamine used to treat another allergic reaction.
[ link to this | view in thread ]
[ link to this | view in thread ]
Re: Re: The whole industry is corrupt and needs reformed
[ link to this | view in thread ]